---
title: "HUTCHMED to Announce 2026 Half-Year Financial Results | HCM Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291249052.md"
description: "HUTCHMED (China) Limited will announce its interim financial results for the six months ended June 30, 2026, on July 30, 2026. Management will host English and Chinese webcasts to discuss the results and answer questions from analysts and investors."
datetime: "2026-06-30T00:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291249052.md)
  - [en](https://longbridge.com/en/news/291249052.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291249052.md)
---

# HUTCHMED to Announce 2026 Half-Year Financial Results | HCM Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the interim results, followed by Q&A sessions. The English webcast will be held on Thursday, July 30, 2026, at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT. The Chinese (Putonghua) webcast will be held at 8:30 am HKT on Friday, July 31, 2026 (1:30 am BST / 8:30 pm EDT on Thursday, July 30, 2026).

Both webcasts will be available live via the company website at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

**About HUTCHMED**

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

**CONTACTS**

**Investor Enquiries**

+852 2121 8200 / ir@hutch-med.com

**Media Enquiries**

FTI Consulting –

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Tim Stamper

+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)

Brunswick – Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

**Panmure Liberum**

_Nominated Advisor and Joint Broker_

Atholl Tweedie / Emma Earl / Rupert Dearden

+44 20 7886 2500

**Cavendish**

_Joint Broker_

Geoff Nash / Nigel Birks

+44 20 7220 0500

**Deutsche Numis**

_Joint Broker_

Duncan Monteith / Ramin Naji

+44 20 7545 8000

### Related Stocks

- [00013.HK](https://longbridge.com/en/quote/00013.HK.md)
- [HCM.US](https://longbridge.com/en/quote/HCM.US.md)
- [FCN.US](https://longbridge.com/en/quote/FCN.US.md)

## Related News & Research

- [HUTCHMED (China): Oncology sales surged over 40% in China, global launches expanded, and cash reserves remained strong](https://longbridge.com/en/news/294357093.md)
- [HUTCHMED H1 FY26 net income drops to USD 15.9 million; revenue rises 0.22% to USD 278.3 million](https://longbridge.com/en/news/294352481.md)
- [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md)
- [Ciena's Q3 2026 Earnings: What to Expect](https://longbridge.com/en/news/293952665.md)
- [Equatorial Energia updates financial calendar for 2026 disclosures](https://longbridge.com/en/news/294368263.md)